Amid growing demand for stricter compliance with safety and quality control norms for medical products, the Centre is framing a new law to strengthen the legal framework for drug quality testing and market surveillance, along with improved regulation of medical devices and cosmetics.
One of the major reasons behind drafting this legislation is the repeated complaints and concerns raised by global health regulators, including the WHO, regarding serious quality lapses by some Indian drug manufacturers.
The draft of the “Drugs, Medical Devices and Cosmetics Act 2025,” which the government plans to introduce in the upcoming Winter Session of Parliament, was presented by Drugs Controller General of India (DCGI) Dr. Rajeev Raghuvanshi during a high-level Union Health Ministry meeting held on Tuesday, according to sources.
